Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Levaquin Patent Upheld In Mylan Challenge

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan's ANDA infringes on valid patent, West Virginia district court finds. Patent protection runs until at least December 2010. J&J still faces litigation on the antibiotic from four other generic companies, but no trial date has been set.

You may also be interested in...



J&J Ditropan XL Patent Invalidated In Mylan Suit

Mylan win evens score before W.Va. District Court judge who had previously ruled J&J's Levaquin patents were valid and infringed.

J&J Ditropan XL Patent Invalidated In Mylan Suit

Mylan win evens score before W.Va. District Court judge who had previously ruled J&J's Levaquin patents were valid and infringed.

Mylan Dismisses “Authorized” Generic Antitrust Claims In W.Va. Lawsuit

Company instead is pressing on with antitrust claims filed in a March 2004 lawsuit in San Francisco state court stemming from Procter & Gamble and Watson’s “authorized” generic agreement for Macrobid. The West Virginia litigation would have been duplicative of the California claims, Mylan says.

Related Content

Topics

UsernamePublicRestriction

Register

PS058471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel